Table 1 Characteristics of basket trials for symptomatic agents in neurodegenerative disorders

Alprazolam

1

Reduced anxiety

HD, AD

Ampreloxetine

1

Control of orthostatic hypotension

PD, MSA

Apomorphine

1

Pain control

CBD, PSP

Armodafinil

1

Improved attention, cognitive enhancement

PD, DLB

AVP-786

1

Reduced disinhibition

DLB, AD, PSP, HD, FTLD

AVP-923

2

Control of pseudobulbar affect

AD, PD, HD, ALS

Botulinum toxin

1

Reduction of rigidity

AD, FTLD

Cannabis

2

Improved sense of well-being, improved quality of life; reduction of pain, nausea, vomiting

PD, CTE, ALS

Carbidopa

1

Improved motor function

MSA, PD

Droxidopa

7

Improved motor and non-motor symptoms, increased blood pressure

PD, MSA, PSP

Entacapone

1

Improved motor function

MSA, PD

Incobotulinum Toxin A

2

Reduced salivary volume

PD, ALS, MSA, PSP

Intepirdine (RVT-101)

1

Improved gait

DLB, AD, PD

Lithium

1

Improved quality of life, reduced depression

CBD, PSP

LY31544207

1

Cognitive enhancement

DLB, PD

Memantine

2

Cognitive enhancement

PD, DLB, FTLD, ALS

Midodrine

4

Control of orthostatic hypotension

MSA, PD

MP-101

1

Reduction of dementia-related psychosis

AD, FTLD, PD, DLB

Nebivolol

1

Control of hypotension

MSA, PD

Nelotanserin

3

Reduced REM sleep behavior disorders, reduced visual hallucinations

PD, DLB

NYX-458

1

Cognitive enhancement

PD, DLB

Pimavanserin

2

Reduction of dementia-related psychosis with delusions and hallucinations

AD, PD, DLB, FTLD

Ramalteon

1

Improved sleep efficiency

HD, DLB, PD

Rimabotulinum toxin B

1

Reduced sialorrhea

PD, ALS

TD-9855

1

Reduced orthostatic hypotension

MSA, PD